2,210 reports of this reaction
1.8% of all TOPIRAMATE SPINKLE reports
#9 most reported adverse reaction
DIZZINESS is the #9 most commonly reported adverse reaction for TOPIRAMATE SPINKLE, manufactured by Advagen Pharma Ltd. There are 2,210 FDA adverse event reports linking TOPIRAMATE SPINKLE to DIZZINESS. This represents approximately 1.8% of all 124,712 adverse event reports for this drug.
TOPIRAMATE SPINKLE has an overall safety score of 85 out of 100. Patients taking TOPIRAMATE SPINKLE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is a less commonly reported adverse event for TOPIRAMATE SPINKLE, but still significant enough to appear in the safety profile.
In addition to dizziness, the following adverse reactions have been reported for TOPIRAMATE SPINKLE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 2,210 FDA reports for TOPIRAMATE SPINKLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 1.8% of all adverse event reports for TOPIRAMATE SPINKLE, making it a notable side effect.
If you experience dizziness while taking TOPIRAMATE SPINKLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.